Cho n'din catherine Boni, Côte d'Ivoire

university Félix Houphouet Boigny Abidjan Microbiologie

Presenter Of 1 Presentation

PAEDIATRICS MENINGITIS SURVEILLANCE IN CÔTE D’IVOIRE AND USE OF IB-VPD/PBM TO MONITOR PCV IMPACT (ID 201)

Abstract

Background

National paediatric bacterial meningitis (PBM) surveillance began in 2002 in Côte d’Ivoire. This surveillance is under the supervision of the immunization program. The aim of this work was to describe the PBM surveillance in Côte d’Ivoire and use of IB-VPD/PBM to monitor PCV impact.

Methods

The paediatric service notifies suspected cases, collect and send the CSF samples to the laboratory. The laboratory receives and analyse CSF and do the management of data. The technical, logistical and financial support were provided by WHO, CDC and Regional Laboratory of GAMBIA MRC. The national immunization program provided feedback to central level.

Results

From January 2002 to December 2019, 7769 CSF samples were submitted to the sentinel site laboratory. Of these samples, 263(3.39%) gave a positive culture with bacterial growth. S. pneumoniae, 50.57% (133 /263) H. influenzae 30.08 (87 /263) and 5.7 % (15/263) N. meningitidies over all the years of monitoring. Pneumococcal conjugate vaccine (PCV) serotypes, 5, 18C, 19F and 6A/B were identified post-vaccine introduction.

Conclusions

This surveillance generated data used for to evidence of disease burden, and advocacy to introduce in routine immunization Pneumococcal conjugate vaccine -13 (PCV 13) in 2014.

Hide

Author Of 2 Presentations

PAEDIATRICS MENINGITIS SURVEILLANCE IN CÔTE D’IVOIRE AND USE OF IB-VPD/PBM TO MONITOR PCV IMPACT (ID 201)

Abstract

Background

National paediatric bacterial meningitis (PBM) surveillance began in 2002 in Côte d’Ivoire. This surveillance is under the supervision of the immunization program. The aim of this work was to describe the PBM surveillance in Côte d’Ivoire and use of IB-VPD/PBM to monitor PCV impact.

Methods

The paediatric service notifies suspected cases, collect and send the CSF samples to the laboratory. The laboratory receives and analyse CSF and do the management of data. The technical, logistical and financial support were provided by WHO, CDC and Regional Laboratory of GAMBIA MRC. The national immunization program provided feedback to central level.

Results

From January 2002 to December 2019, 7769 CSF samples were submitted to the sentinel site laboratory. Of these samples, 263(3.39%) gave a positive culture with bacterial growth. S. pneumoniae, 50.57% (133 /263) H. influenzae 30.08 (87 /263) and 5.7 % (15/263) N. meningitidies over all the years of monitoring. Pneumococcal conjugate vaccine (PCV) serotypes, 5, 18C, 19F and 6A/B were identified post-vaccine introduction.

Conclusions

This surveillance generated data used for to evidence of disease burden, and advocacy to introduce in routine immunization Pneumococcal conjugate vaccine -13 (PCV 13) in 2014.

Hide